Antalarmin

From Self-sufficiency
Revision as of 03:22, 28 March 2010 by Drphilharmonic (Talk) (logic)

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to: navigation, search
Antalarmin
180px
Systematic (IUPAC) name
N-butyl-N-ethyl-2,5,6-trimethyl-7-(2,4,6-trimethylphenyl)pyrrolo[3,2-e]pyrimidin-4-amine
Legal status
Legal status
  • Legal
Identifiers
CAS Number 157284-96-3
ATC code none
PubChem CID 177990
Synonyms Antalarmin
Chemical data
Formula C24H34N4
Molar mass 378.55 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Antalarmin is a drug that acts as a CRF-1 antagonist.

Corticotropin-releasing factor (CRF), also known as Corticotropin-releasing hormone, is an endogenous peptide hormone released in response to various triggers such as chronic stress and drug addiction. This, then, triggers the release of corticotropin (ACTH), another hormone involved in the physiological response to stress. Chronic release of CRF and ACTH is believed to be directly or indirectly involved in many of the harmful physiological effects of chronic stress, such as excessive glucocorticoid release, stomach ulcers, anxiety, diabetes mellitus, osteoporosis, depression, and development of high blood pressure and consequent cardiovascular problems.[1]

Antalarmin is a non-peptide drug that blocks the CRF-1 receptor, and, as a consequence, reduces the release of ACTH in response to chronic stress.[2] This has been demonstrated in animals to reduce the behavioural responses to stressful situations,[3] and it is proposed that antalarmin itself, or more likely newer CRF antagonist drugs still under development,[4] could be useful for reducing the adverse health consequences of chronic stress in humans, as well as having possible uses in the treatment of conditions such as anxiety, depression, and drug addiction.[5]

Results so far have had limited success, with various CRF antagonists being tested, which showed some antidepressant effects, but failed to produce an effect comparable with conventional antidepressant drugs.[6] However more positive results were seen when antalarmin was combined with an SSRI antidepressant, suggesting a potential for synergistic effect.[7] Encouraging results have also been observed using antalarmin as a potential treatment for anxiety[8][9] and stress-induced hypertension.[10]

Chronic antalarmin treatment also showed anti-inflammatory effects and has been suggested as having potential uses in the treatment of inflammatory conditions such as arthritis,[11] as well as stress-induced gastrointestinal ulcers[12] and irritable bowel syndrome.[13][14]

Mixed results have been seen in research into the use of antalarmin and other CRF-1 antagonists in the treatment of drug addiction disorders. Tests of antalarmin on cocaine use in cocaine-addicted monkeys produced only slight reductions of use that were not statistically significant,[15] however in tests on cocaine-addicted rats, antalarmin did prevent dose escalation with prolonged use, suggesting that it might stabilise cocaine use and prevent it increasing over time, although without consistently reducing it.[16]

Antalarmin also showed positive effects in reducing withdrawal syndrome from chronic opioid use,[17] and significantly reduced self-administration of ethanol in ethanol-addicted rodents.[18][19][20]


See also

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

External links


GABAA PAMs
Others
α2δ VDCC Blockers
5-HT1A Agonists
Azapirones: Buspirone • Gepirone • Tandospirone; Others: Flesinoxan • Oxaflozane
H1 Antagonists
Diphenylmethanes: Captodiame • Hydroxyzine; Others: Brompheniramine • Chlorpheniramine • Pheniramine
CRH1 Antagonists
Antalarmin • CP-154,526 • Pexacerfont • Pivagabine
NK2 Antagonists
MCH1 antagonists
mGluR2/3 Agonists
mGluR5 NAMs
TSPO agonists
σ1 agonists
Others

M: PSO/PSI

dsrd (o, p, m, p, a, d, s), sysi/epon, spvo

proc, drug(N5A/5B/5C/6A/6B/6D)

  1. ↑ Zoumakis E, Rice KC, Gold PW, Chrousos GP. Potential uses of corticotropin-releasing hormone antagonists. Annals of the New York Academy of Sciences. 2006 Nov;1083:239-51.
  2. ↑ Webster EL, Lewis DB, Torpy DJ, Zachman EK, Rice KC, Chrousos GP. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) receptor antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology. 1996 Dec;137(12):5747-50.
  3. ↑ Deak T, Nguyen KT, Ehrlich AL, Watkins LR, Spencer RL, Maier SF, Licinio J, Wong ML, Chrousos GP, Webster E, Gold PW. The impact of the nonpeptide corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to stress. Endocrinology. 1999 Jan;140(1):79-86.
  4. ↑ Nielsen DM, Carey GJ, Gold LH. Antidepressant-like activity of corticotropin-releasing factor type-1 receptor antagonists in mice. European Journal of Pharmacology. 2004 Sep 19;499(1-2):135-46.
  5. ↑ McCarthy JR, Heinrichs SC, Grigoriadis DE. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications. Current Pharmaceutical Design. 1999 May;5(5):289-315.
  6. ↑ Jutkiewicz EM, Wood SK, Woods JH. The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced swim test and on swim-induced increases in adrenocorticotropin in rats. Psychopharmacology (Berlin). 2005 July; 180(2): 215–223.
  7. ↑ Ducottet C, Griebel G, Belzung C. Effects of the selective nonpeptide corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of depression in mice. Progress in Neuropsychopharmacology and Biological Psychiatry. 2003 Jun;27(4):625-31.
  8. ↑ Zorrilla EP, Valdez GR, Nozulak J, Koob GF, Markou A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Research. 2002 Oct 18;952(2):188-99.
  9. ↑ Habib KE, Weld KP, Rice KC, Pushkas J, Champoux M, Listwak S, Webster EL, Atkinson AJ, Schulkin J, Contoreggi C, Chrousos GP, McCann SM, Suomi SJ, Higley JD, Gold PW. Oral administration of a corticotropin-releasing hormone receptor antagonist significantly attenuates behavioral, neuroendocrine, and autonomic responses to stress in primates. Proceedings of the National Academy of Sciences USA. 2000 May 23;97(11):6079-84.
  10. ↑ Briscoe RJ, Cabrera CL, Baird TJ, Rice KC, Woods JH. Antalarmin blockade of corticotropin releasing hormone-induced hypertension in rats. Brain Research. 2000 Oct 27;881(2):204-7.
  11. ↑ Webster EL, Barrientos RM, Contoreggi C, Isaac MG, Ligier S, Gabry KE, Chrousos GP, McCarthy EF, Rice KC, Gold PW, Sternberg EM. Corticotropin releasing hormone (CRH) antagonist attenuates adjuvant induced arthritis: role of CRH in peripheral inflammation. Journal of Rheumatology. 2002 Jun;29(6):1252-61.
  12. ↑ Gabry KE, Chrousos GP, Rice KC, Mostafa RM, Sternberg E, Negrao AB, Webster EL, McCann SM, Gold PW. Marked suppression of gastric ulcerogenesis and intestinal responses to stress by a novel class of drugs. Molecular Psychiatry. 2002;7(5):474-83, 433.
  13. ↑ Greenwood-Van Meerveld B, Johnson AC, Cochrane S, Schulkin J, Myers DA. Corticotropin-releasing factor 1 receptor-mediated mechanisms inhibit colonic hypersensitivity in rats. Neurogastroenterology and Motility. 2005 Jun;17(3):415-22.
  14. ↑ Martinez V, Taché Y. CRF1 receptors as a therapeutic target for irritable bowel syndrome. Current Pharmaceutical Design. 2006;12(31):4071-88.
  15. ↑ Mello NK, Negus SS, Rice KC, Mendelson JH. Effects of the CRF1 antagonist antalarmin on cocaine self-administration and discrimination in rhesus monkeys. Pharmacology, Biochemistry and Behaviour. 2006 Dec;85(4):744-51.
  16. ↑ Specio SE, Wee S, O’Dell LE, Boutrel B, Zorrilla EP and Koob GF. CRF1 receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology (Berlin). 2008 Feb;196(3):473-482.
  17. ↑ Stinus L, Cador M, Zorrilla EP, Koob GF. Buprenorphine and a CRF1 antagonist block the acquisition of opiate withdrawal-induced conditioned place aversion in rats. Neuropsychopharmacology. 2005 Jan;30(1):90-8.
  18. ↑ Funk CK, Zorrilla EP, Lee MJ, Rice KC, Koob GF. Corticotropin-releasing factor 1 antagonists selectively reduce ethanol self-administration in ethanol-dependent rats. Biological Psychiatry. 2007 Jan 1;61(1):78-86.
  19. ↑ Chu K, Koob GF, Cole M, Zorrilla EP, Roberts AJ. Dependence-induced increases in ethanol self-administration in mice are blocked by the CRF1 receptor antagonist antalarmin and by CRF1 receptor knockout. Pharmacology, Biochemistry and Behaviour. 2007 Apr;86(4):813-21.
  20. ↑ Marinelli PW, Funk D, Juzytsch W, Harding S, Rice KC, Shaham Y, Lê AD. The CRF1 receptor antagonist antalarmin attenuates yohimbine-induced increases in operant alcohol self-administration and reinstatement of alcohol seeking in rats. Psychopharmacology (Berlin). 2007 Dec;195(3):345-55.
Retrieved from "http://ssf.f15ijp.com/wiki/index.php?title=Antalarmin&oldid=22709"